Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets - 26/10/07
pages | 2 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
We compared the changes in weight (kg) and body mass index (BMI) (kg/m2) in 52 hospitalized adolescents between baseline and after 12 weeks of monotherapy with either (i) olanzapine (OLZ) orally disintegrating tablets (ODT) (N=16; 16.6mg/day±4.4 [SD]), or (ii) OLZ standard oral tablets (SOT) (N=10; 18.0mg/day±4.2), or (iii) risperidone (N=26; 2.8mg/day±1.2). Significantly greater increases in mean weight and BMI were observed in the patients treated with OLZ SOT (8.9±5.1 [SD] kg; 1.9±0.6kg/m2, respectively) than in those with ODT (3.0±2.1kg; 1.1±0.8kg/m2). Similarly, OLZ ODT treatment was associated with significantly greater increases in weight and BMI than risperidone (1.0±1.8kg; 0.4±0.7kg/m2). These findings suggest that adolescents gain less weight with OLZ ODT than OLZ SOT, possibly because the former formulation shortens the time of interaction with digestive serotonin receptors mediating satiety.
Le texte complet de cet article est disponible en PDF.Keywords : Olanzapine, Orally disintegrating tablets, Weight gain, BMI, Adolescents
Plan
Vol 22 - N° 7
P. 453-454 - octobre 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?